Nanoviricides (NNVC) EBIT (2010 - 2026)

Nanoviricides has disclosed EBIT across 17 years of filings, most recently posting -$2.0 million for Q1 2026.

• In Q1 2026, EBIT rose 9.73% year-over-year to -$2.0 million; the TTM figure through Mar 2026 stood at -$8.2 million (up 17.14% YoY), while the FY2025 annual figure was -$9.6 million, down 12.63% from the prior year.
• EBIT came in at -$2.0 million for Q1 2026 at Nanoviricides, up from -$2.2 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$1.6 million in Q3 2022 to a low of -$3.7 million in Q2 2023.
• Average EBIT over 5 years is -$2.2 million, with a median of -$2.0 million recorded in 2023.
• Year-over-year, EBIT sank 105.07% in 2023 and surged 43.28% in 2025.
• Over 5 years, EBIT stood at -$1.8 million in 2022, then fell by 19.13% to -$2.2 million in 2023, then rose by 5.75% to -$2.1 million in 2024, then declined by 8.46% to -$2.2 million in 2025, then rose by 9.09% to -$2.0 million in 2026.
• Per Business Quant data, the three most recent EBIT figures were -$2.0 million in Q1 2026, -$2.2 million in Q4 2025, and -$1.8 million in Q3 2025.